National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Guidelines® with NCCN Evidence Blocks™, and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 4.2017. 

  • Metastatic Disease – Sensitizing EGFR Mutation Positive (NSCL-19)
    • Osimertinib changed from a category 2A to a category 1 recommendation.
    • Footnote "nn" modified with this addition: Consider reflex to tissue-based testing, if plasma test is negative for the T790M mutation.
  • Metastatic Disease - Subsequent Therapy (NSCL-24/NSCL-25)
    • PS 0-2: Atezolizumab changed from a category 2A to a category 1 recommendation.

*For your reference, the previous update (Version 3.2017) to the NCCN Guidelines for Non-Small Cell Lung Cancer, published on November 16, 2016, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

 

NCCN has published updates to the NCCN Guidelines for Adolescent and Young Adult Oncology. These NCCN Guidelines are currently available as Version 2.2017. 

  • Updated the Age-Specific Incidences of Cancer by Age Group and Sex in the AYA Population (2009-2013) table and reference. (AYAO-4)
  • The Discussion section has been updated to reflect the changes in the algorithm. 

*For your reference, the previous update (Version 1.2017) to the NCCN Guidelines for Adolescent and Young Adult Oncology, published on October 10, 2016, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf


NCCN has published NCCN Guidelines with NCCN Evidence Blocks™ for the following cancer types: 

  • Penile Cancer, Version 1.2017
  • Prostate Cancer, Version 1.2017


For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content.

Subscribe to NCCN Flash Updates™